Cargando…
Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo
Bispecific antibodies, which can bind to two different epitopes on the same or different antigens simultaneously, have recently emerged as attractive candidates for study in various diseases. Our present study successfully constructs and expresses a fully human, bispecific, single-chain diabody (BsD...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213929/ https://www.ncbi.nlm.nih.gov/pubmed/30257416 http://dx.doi.org/10.3390/ijms19102900 |
_version_ | 1783367890374754304 |
---|---|
author | Xiong, Chenghao Mao, Yingqing Wu, Tao Kang, Nannan Zhao, Mingjun Di, Rongrong Li, Xiaoping Ji, Xuemei Liu, Yu |
author_facet | Xiong, Chenghao Mao, Yingqing Wu, Tao Kang, Nannan Zhao, Mingjun Di, Rongrong Li, Xiaoping Ji, Xuemei Liu, Yu |
author_sort | Xiong, Chenghao |
collection | PubMed |
description | Bispecific antibodies, which can bind to two different epitopes on the same or different antigens simultaneously, have recently emerged as attractive candidates for study in various diseases. Our present study successfully constructs and expresses a fully human, bispecific, single-chain diabody (BsDb) that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 (PD-1) in Pichia pastoris. Under the optimal expression conditions (methanol concentration, 1%; pH, 4.0; inoculum density, OD600 = 4, and the induction time, 96 h), the maximum production level of this BsDb is achieved at approximately 20 mg/L. The recombinant BsDb is purified in one step using nickel-nitrilotriacetic acid (Ni-NTA) column chromatography with a purity of more than 95%. Indirect enzyme-linked immune sorbent assay (ELISA) and sandwich ELISA analyses show that purified BsDb can bind specifically to VEGF165 and PD-1 simultaneously with affinities of 124.78 nM and 25.07 nM, respectively. Additionally, the BsDb not only effectively inhibits VEGF165-stimulated proliferation, migration, and tube formation in primary human umbilical vein endothelial cells (HUVECs), but also significantly improves proliferation and INF-γ production of activated T cells by blocking PD-1/PD-L1 co-stimulation. Furthermore, the BsDb displays potent antitumor activity in mice bearing HT29 xenograft tumors by inhibiting tumor angiogenesis and activating immune responses in the tumor microenvironment. Based on these results, we have prepared a potential bispecific antibody drug that can co-target both VEGF165 and PD-1 for the first time. This work provides a stable foundation for the development of new strategies by the combination of an angiogenesis inhibition and immune checkpoint blockade for cancer therapy. |
format | Online Article Text |
id | pubmed-6213929 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-62139292018-11-14 Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo Xiong, Chenghao Mao, Yingqing Wu, Tao Kang, Nannan Zhao, Mingjun Di, Rongrong Li, Xiaoping Ji, Xuemei Liu, Yu Int J Mol Sci Article Bispecific antibodies, which can bind to two different epitopes on the same or different antigens simultaneously, have recently emerged as attractive candidates for study in various diseases. Our present study successfully constructs and expresses a fully human, bispecific, single-chain diabody (BsDb) that can bind to vascular endothelial growth factor 165 (VEGF165) and programmed death-1 (PD-1) in Pichia pastoris. Under the optimal expression conditions (methanol concentration, 1%; pH, 4.0; inoculum density, OD600 = 4, and the induction time, 96 h), the maximum production level of this BsDb is achieved at approximately 20 mg/L. The recombinant BsDb is purified in one step using nickel-nitrilotriacetic acid (Ni-NTA) column chromatography with a purity of more than 95%. Indirect enzyme-linked immune sorbent assay (ELISA) and sandwich ELISA analyses show that purified BsDb can bind specifically to VEGF165 and PD-1 simultaneously with affinities of 124.78 nM and 25.07 nM, respectively. Additionally, the BsDb not only effectively inhibits VEGF165-stimulated proliferation, migration, and tube formation in primary human umbilical vein endothelial cells (HUVECs), but also significantly improves proliferation and INF-γ production of activated T cells by blocking PD-1/PD-L1 co-stimulation. Furthermore, the BsDb displays potent antitumor activity in mice bearing HT29 xenograft tumors by inhibiting tumor angiogenesis and activating immune responses in the tumor microenvironment. Based on these results, we have prepared a potential bispecific antibody drug that can co-target both VEGF165 and PD-1 for the first time. This work provides a stable foundation for the development of new strategies by the combination of an angiogenesis inhibition and immune checkpoint blockade for cancer therapy. MDPI 2018-09-25 /pmc/articles/PMC6213929/ /pubmed/30257416 http://dx.doi.org/10.3390/ijms19102900 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Xiong, Chenghao Mao, Yingqing Wu, Tao Kang, Nannan Zhao, Mingjun Di, Rongrong Li, Xiaoping Ji, Xuemei Liu, Yu Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo |
title | Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo |
title_full | Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo |
title_fullStr | Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo |
title_full_unstemmed | Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo |
title_short | Optimized Expression and Characterization of a Novel Fully Human Bispecific Single-Chain Diabody Targeting Vascular Endothelial Growth Factor165 and Programmed Death-1 in Pichia pastoris and Evaluation of Antitumor Activity In Vivo |
title_sort | optimized expression and characterization of a novel fully human bispecific single-chain diabody targeting vascular endothelial growth factor165 and programmed death-1 in pichia pastoris and evaluation of antitumor activity in vivo |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213929/ https://www.ncbi.nlm.nih.gov/pubmed/30257416 http://dx.doi.org/10.3390/ijms19102900 |
work_keys_str_mv | AT xiongchenghao optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT maoyingqing optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT wutao optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT kangnannan optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT zhaomingjun optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT dirongrong optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT lixiaoping optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT jixuemei optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo AT liuyu optimizedexpressionandcharacterizationofanovelfullyhumanbispecificsinglechaindiabodytargetingvascularendothelialgrowthfactor165andprogrammeddeath1inpichiapastorisandevaluationofantitumoractivityinvivo |